FDA grants Fast Track Designation for eganelisib in combination with checkpoint inhibitor and chemotherapy for first-line treatment of patients with inoperable locally advanced or metastatic triple-negative breast cancer

Company is currently enrolling patients in MARIO-3, its ongoing phase II study in collaboration with Roche/Genentech to evaluate eganelisib, a first-in-class, oral therapy that selectively inhibits PI3K-gamma, in combination with atezolizumab & Abraxane (albumin bound paclitaxel)

Biospace Inc.